Susquehanna Fundamental Investments LLC Invests $1.49 Million in Omeros Co. (NASDAQ:OMER)

Susquehanna Fundamental Investments LLC acquired a new stake in Omeros Co. (NASDAQ:OMER - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 150,557 shares of the biopharmaceutical company's stock, valued at approximately $1,488,000. Susquehanna Fundamental Investments LLC owned approximately 0.26% of Omeros as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Virtus ETF Advisers LLC bought a new position in shares of Omeros in the 4th quarter worth $83,000. Price T Rowe Associates Inc. MD boosted its position in shares of Omeros by 12.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company's stock valued at $392,000 after buying an additional 4,401 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 1,972 shares during the last quarter. Marshall Wace LLP bought a new stake in Omeros during the fourth quarter worth $437,000. Finally, XTX Topco Ltd bought a new position in Omeros during the 4th quarter valued at $206,000. 48.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

OMER has been the topic of a number of recent analyst reports. D. Boral Capital reissued a "buy" rating and set a $36.00 price target on shares of Omeros in a research report on Friday, April 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. Finally, StockNews.com lowered Omeros from a "hold" rating to a "sell" rating in a report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Trading Down 1.8 %

Omeros stock traded down $0.12 on Tuesday, hitting $6.69. 117,512 shares of the stock traded hands, compared to its average volume of 582,519. The business's fifty day simple moving average is $7.59 and its 200 day simple moving average is $8.12. The firm has a market cap of $390.07 million, a P/E ratio of -2.87 and a beta of 2.42. Omeros Co. has a 1 year low of $3.00 and a 1 year high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.08. During the same quarter in the previous year, the firm posted ($0.15) EPS. As a group, analysts predict that Omeros Co. will post -3.09 earnings per share for the current year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.